K risten M. Hege, MD, is one of those rare individuals who excels at most of her endeavors. She can get something done herself, and she can exhibit the leadership necessary to bring teams together to tackle problems that cannot be solved alone. Hege is a physician, research scientist, teacher and mentor, as well as a wife and mother of two daughters. In her free time, she likes to scale mountains — or sometimes strap on a pair of skis and carve her own groove on the way back down. Hege — senior vice president of early clinical development for hematology/oncology and cell therapy at Bristol Myers Squibb — helped develop idecabtagene vicleucel (Abecma; Bristol Myers Squibb, 2seventybio), the first commercially available chimeric antigen receptor T-cell therapy for treatment of advanced multiple myeloma. The development of B-cell maturation antigen (BCMA)-targeted CAR T-cell therapies like idecabtagene vicleucel — often called ide-cel — may be the most clinically impactful advance for the disease. “An opportunity for cure — I think that’s why we are all in this,” Hege told Healio | Cell Therapy Next. The success of leading Bristol Myers Squibb’s ide-cel clinical program from first patient treated to regulatory approval […]
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
